MET and non-small cell lung carcinoma: In a retrospective study of East Asian patients with NSCLC, 18 patients with stage IV NSCLC harbouring MET exon 14 skipping who did not receive a targeted MET inhibitor achieved a median OS of 6.7 months (6).